Veranex and Sus Clinicals Announce Strategic Collaboration to Advance Medical Device Research

RALEIGH, NC and CINCINNATI, OH — [August 18, 2026] — Veranex, the industry’s first Innovation CRO offering end-to-end services across the MedTech development lifecycle, and Sus Clinicals, a pioneer in genetically modified large-animal cancer models, today announced a strategic collaboration to deliver preclinical solutions that accelerate promising medical device innovations toward the clinic.

By leveraging Veranex’s demonstrated expertise in providing end-to-end research services to medical device clients, and Sus Clinicals’ proprietary research platform, this collaboration can deliver significant benefits which will advance medical device development.

Sherry Farrugia, Senior Vice President of Preclinical Services at Veranex, said: “We are delighted to be working with Sus Clinicals. Theirs is the only inducible transgenic large animal platform capable of generating human-like tumors on demand.”

By combining Veranex’s expertise, facilities, and capabilities with Sus Clinicals’ innovative platform, the collaboration will help researchers accelerate the path to the clinic. With complementary strengths, proven track records, and a strategic fit, both organizations are positioned to advance the next wave of preclinical innovation.

“We are privileged to be working with the team at Veranex,” said Jessicca Rege, Ph.D., Chief Executive Officer of Sus Clinicals. “Their depth of experience and expertise in preclinical research services and their established connections in the industry will allow us to offer our Oncopig® more broadly than we could alone.”

About Veranex

Veranex is a global, fully integrated Innovation CRO dedicated to accelerating MedTech innovation from early concept through commercialization. Headquartered in Raleigh, N.C., and powered by more than 800 specialists worldwide, Veranex combines design & engineering, preclinical, clinical, regulatory, manufacturing, and market access expertise to deliver clarity, confidence, and speed—turning vision into velocity for device and diagnostics innovators.

For more information, visit Veranex.com

About Sus Clinicals

Sus Clinicals accelerates the qualification of potentially life-saving cancer therapeutics through its proprietary Oncopig^® platform. In collaboration with top CROs and research institutions with large animal testing capability, Sus Clinicals’ predictive model better identifies drugs, diagnostics, and devices with the highest potential for success in human clinical trials.​ Sus Clinicals is headquartered in Cincinnati, with its scientific team based in Chicago.

For more information, visit Susclinicals.com